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ABSTRACT
Background    There is accumulating evidence that 
shows cell-mediated immunity regulated by T cells is 
impaired in cancer patients. Unfortunately, the mecha-
nisms by which B cells participate in tumor immunity 
are only partially understood. 
Methods    The serum concentration of Immunoglobu-
lin G (IgG) was measured by Enzyme-Linked Immuno-
Sorbent Assay (ELISA) in patients with gastric cancer. 
Immunohistochemistry was also performed using the 
anti- cluster of differentiation (CD)134 antibody to eval-
uate the number of plasma cells in the tumor tissue. 
Results    The total serum IgG concentration was sig-
nificantly lower in patients with lymph node metastasis 
compared with patients without metastasis. The serum 
concentration of total IgG at stage III/IV was signifi-
cantly lower compared with tumors classified as stage 
I/II. A decreased serum concentration of total IgG and 
IgG1 was significantly related to a poor prognosis for 
gastric cancer patients. Furthermore, multivariate anal-
ysis indicated that the serum concentration of IgG and 
lymph node metastasis were independent prognostic in-
dicators for poorer survival. The number of plasma cells 
was significantly lower in gastric cancer tissue compared 
with non-cancerous gastric mucosa. 
Conclusion    A decreased serum concentration of IgG 
was closely related to poor prognosis, indicating the pos-
sibility that impaired antibody-mediated immunity is as-
sociated with tumor progression in patients with gastric 
cancer.
Key words    B cell; gastric cancer; IgG; plasma cell; 
prognosis
Because of the success of immune-checkpoint inhibi-
tors in the treatment of various tumor types,1-3 such as 
antibodies for programmed cell death protein 1 and 
cytotoxic T-lymphocyte antigen-4, it is now clear that 
effective immunity against cancer cells can be induced 
in cancer patients. However, the spontaneous rejection 
of established cancers is rare because cancers frequently 
use physiological immunosuppressive mechanisms to 
escape host immunity, a phenomenon known as “tumor 
immune evasion.” 
 The immune system can be divided into two branch-
es, humoral immunity and cellular immunity. Numerous 
reports indicated that the function of T cells that play 
leading part of cell-mediated immunity is impaired by 
immunosuppressive cytokines including interleukin (IL)-
10 and transforming growth factor-beta by cancer cells 
and cancer stromal cells,4 and up-regulation of immune 
checkpoint molecules such as programmed cell death-1 
and T cell immunoglobulin and mucin domain-3.5, 6 
Regulatory T cells (Treg), described as cluster of differ-
entiation (CD) 4+CD25+Foxp3+ cells and constituting 
around 10% of peripheral CD4+ T cells, are crucial for 
maintaining immune self-tolerance and homeostasis, 
and are also involved in dysfunctional T cells.7, 8 Regu-
latory T cell populations are increased in the blood and 
tumor tissue of cancer patients and are closely correlated 
with the progression of various types of cancer via im-
munosuppression.9–11
 B lymphocytes are important in adaptive immu-
nity and antibody-mediated immune response. B cells 
respond to a variety of stimuli that cause them to differ-
entiate, undergo class switching, and produce antibodies 
of specific classes and subclasses. Human B cells are 
known to produce four subclasses of Immunoglobulin 
G (IgG)—IgG1, IgG2, IgG3, and IgG4—with each sub-
class having a different biological function.12 In healthy 
adult blood serum, IgG1, IgG2, IgG3, and IgG4 repre-
sent 65, 25, 6, and 4% of the total IgG, respectively, but 
these ratios may be altered by certain diseases.13 The 
antibody types vary in their ability to activate immune 
system components, including the formation of comple-
mentary complexes or the engagement of Fc receptors 
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on the surface of effector cells.14 In contrast to T cells, 
the mechanisms by which B cells participate in tumor 
immunity are only partially understood.15
 Gastric cancer is one of the most common cancers 
in Asia and has the second highest mortality rate among 
all cancers worldwide.16 Despite the expression of tumor 
rejection antigens, such as melanoma antigens 1–317 and 
the presence of tumor-specific cytotoxic T cells,18 the 
immune system fails to provide an adequate immune 
response to gastric carcinoma cells, which is similar to 
findings for other cancers. However, the mechanisms 
by which gastric cancer cells overcome antitumor im-
munological responses are poorly understood. Recently, 
some antibody drugs have been shown to be effective 
in the treatment of gastric cancer, indicating that anti-
body-mediated immunity is effective in the treatment of 
gastric cancer; however, little is known about humoral 
immunity in gastric cancer patients. This study sought to 
determine the serum concentration of total IgG and the 
concentration of the IgG subtypes in gastric cancer pa-
tients. From this we evaluated the relationship between 
IgG concentration and cancer progression to determine 
the status of antibody-mediated immunity in patients 
with gastric cancer.
MATERIALS AND METHODS
Patients and normal donors
This study enrolled 100 patients who were pathologi-
cally diagnosed with gastric adenocarcinoma and treat-
ed at Tottori University Hospital. None of the patients 
received radiotherapy, chemotherapy, or other medical 
interventions before surgery. Healthy control patients 
for Enzyme-Linked ImmunoSorbent Assay (ELISA) in-
cluded 27 age-matched subjects (18 men and nine wom-
en; mean age 67.2 ± 10.3 years). There was no patient 
with autoimmune disease included in the current study. 
Institutional review board approval was obtained and all 
patients provided informed consent for blood and tissue 
donations (IRB approval number: 2675). Clinicopatho-
logical findings were generally determined according to 
the 14th edition of the Japanese Classification of Gastric 
Carcinoma.19 
Measurement of serum IgG
Serum samples were collected from the patients prior to 
and 1 month after their operations. The concentrations 
of IgG, IgG1, IgG2, IgG3, and IgG4 were measured by 
ELISA using human IgG, IgG1, IgG2, IgG3, and IgG4 
platinum ELISA kits, respectively (eBioscience, San Di-
ego, CA). 
Immunohistochemistry
Immunohistochemistry was performed in 73 patients. 
Tissue samples were fixed in formalin and embedded in 
paraffin. Serial sections were cut at 4 µm, dewaxed, de-
paraffinized in xylene, and rehydrated through a graded 
alcohol series. For retrieval of CD138, the sections were 
boiled using a microwave oven in citrate buffer (pH 9.0) 
for 15 min. The samples were incubated in 3% hydrogen 
peroxidase for 10 min to block endogenous peroxidases, 
and in Block Ace (DS Pharma Biomedical, Osaka, Ja-
pan) for 20 min to prevent non-specific antigen binding. 
The slides were subsequently incubated with mouse 
monoclonal anti-CD138 (Nichirei, Tokyo, Japan) for 
1 h at room temperature. Secondary antibody binding 
was detected with Histofine MAX-PO (Nichirei). The 
sections were developed using a Histofine DAB solution 
(Nichirei) and counterstained with Mayer’s hematoxylin. 
Each slide was dehydrated through a graded alcohol 
series and covered with a coverslip. The presence of 
cells positive for CD138 on each slide was determined 
in a blinded method. Cells in parts of both non-can-
cerous mucosa and tumor where CD138-positive cells 
were observed most frequently were counted in a ×400 
high-power field.
 
Statistical analysis
Differences between the groups were analyzed using 
paired t tests or Mann–Whitney U tests. Disease specific 
survival (DSS) was calculated according to the Kaplan–
Meier method and compared using the log-rank test. Pa-
tients who died of causes other than gastric cancer were 
considered lost to follow-up at the time of death. The 
Youden index was calculated using receiver operating 
characteristic (ROC) analysis to determine an optimal 
cutoff value for the concentration of IgG in evaluating 
survival analysis. Multivariate analysis of factors prog-
nostic of DSS was performed using Cox’s proportional 
hazards model and a stepwise procedure. Statistical 
significance was defined as P < 0.05. Statistical analyses 
were performed using GraphPad Prism (GraphPad Soft-
ware, La Jolla, CA) and Stat View 5.0 for Windows (SAS 
Institute, Cary, NC) software. 
RESULTS
Serum concentration of IgG and patient clinico-
pathologic characteristics
We first determined the serum concentration of total IgG 
and the concentration of each IgG subclass in both con-
trol and gastric cancer patients. The serum concentration 
of total IgG in gastric cancer patients was significantly 
lower compared with the control patients (P = 0.032; Ta-
ble 1). For the concentrations of the IgG subclasses, the 
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serum concentration of IgG3 in gastric cancer patients 
tended to be lower when compared with the control pa-
tients (P = 0.082; Table 1). The serum concentrations of 
IgG1, IgG2, and IgG4 in the gastric cancer patients were 
lower compared with the control patients, but the differ-
ences were not statistically significant.
 With regard to the correlation between serum con-
centration of IgG and clinicopathologic factors, the total 
serum concentration of IgG was significantly lower in 
Table 2. Relationship between the serum concentration of each IgG subclass and the clinicopathological variables of the 
gastric cancer patients
Variables Total IgG P value IgG1 P value IgG2 P value IgG3 P value IgG4 P value
Age (years) 0.32 0.61 0.59 0.30 0.078
< 70 (n = 59) 872.7 ± 401.9 529.6 ± 408.4 241.6 ± 136.8 32.8 ± 20.9 68.8 ± 62.3
≥ 70 (n = 41) 951.6 ± 427.3 554.5 ± 386.1 258.0 ± 150.1 32.4 ± 32.8 106.8 ± 97.0
Gender 0.71 0.87 0.56 0.38 0.81
Male (n = 76) 908.4 ± 447.9 537.8 ± 424.1 255.9 ± 128.2 32.4 ± 17.5 82.2 ± 84.3
Female (n = 24) 904.0 ± 403.5 540.4 ± 391.8 245.9 ± 146.6 32.7 ± 28.6 85.0 ± 79.4
Depth of invasion* 0.20 0.64 0.26 0.64 0.48
T1 (early) (n = 61) 958.2 ± 441.9 567.8 ± 433.9 266.7 ± 159.2 31.3 ± 26.6 92.5 ± 88.6
T2/3/4 (advanced) (n = 31) 821.9 ± 333.7 496.0 ± 350.4 219.5 ± 105.1 34.8 ± 25.9 71.6 ± 64.0
Lymph node metastasis 0.025 0.096 0.31 0.39 0.92
Absent (n = 67) 979.5 ± 441.8 599.2 ± 439.6 261.3 ± 153.9 31.8 ± 20.1 87.2 ± 84.7
Present (n = 33) 754.0 ± 296.6 419.2 ± 261.1 221.8 ± 111.0 34.4 ± 36.0 78.6 ± 70.9
Histology† 0.88 0.70 0.14 0.87 0.94
Differentiated (n = 55) 885.8 ± 397.8 536.8 ± 367.6 233.9 ± 145.4 32.0 ± 27.7 83.1 ± 71.8
Undifferentiated (n = 45) 928.6 ± 432.6 543.5 ± 435.7 265.9 ± 137.0 33.4 ± 24.7 85.8 ± 90.2
Lymphatic involvement 0.94 0.25 0.47 0.46 0.39
Absent (n = 43) 924.4 ± 467.8 529.5 ± 467.3 273.3 ± 176.7 32.1 ± 30.3 89.4 ± 72.0
Present (n = 57) 890.5 ± 368.5 547.5 ± 340.0 229.4 ± 106.4 33.1 ± 23.0 80.5 ± 86.3
Vascular involvement 0.63 0.84 0.68 0.29 0.28
Absent (n = 57) 930.1 ± 431.7 550.0 ± 434.8 262.1 ± 166.0 30.8 ± 27.6 87.1 ± 69.4
Present (n = 43) 871.9 ± 387.4 526.2 ± 346.7 230.0 ± 100.5 35.1 ± 24.5 80.6 ± 93.3
Stage of disease 0.0085 0.074 0.47 0.066 0.30
I / II (n = 74) 970.3 ± 431.3 587.8 ± 425.0 257.8 ± 153.1 34.1 ± 26.6 90.6 ± 84.3
III / IV (n = 26) 719.3 ± 285.0 403.1 ± 269.1 221.2 ± 101.2 28.6 ± 25.2 66.5 ± 65.2
Serum albumin level 0.27 0.56 0.87 0.97 0.25
≥ 4 g/dL (n = 48) 929.5 ± 394.2 560.8 ± 393.8 247.2 ± 150.8 35.1 ± 31.8 86.5 ± 65.8
< 4 g/dL (n = 52) 882.5 ± 430.8 520.4 ± 404.0 249.3 ± 134.6 30.4 ± 19.8 82.3 ± 92.1
Total lymphocyte count 0.14 0.066 0.32 0.13
≥ 1671 (n = 44) 866.5 ± 385.8 480.0 ± 375.3 280.7 ± 155.6 30.9 ± 29.1 74.9 ± 86.5
< 1671 (n = 56) 935.4 ± 432.9 586.8 ± 411.5 222.8 ± 125.6 34.0 ± 24.0 91.8 ± 74.7
All results expressed as means ± SD. 
*Depth of invasion: T1, tumor invasion of the lamina propria or submucosa; T2, tumor invasion of the muscularis propria; T3, tumor in-
vasion of the subserosa; T4, tumor penetration of the serosa or tumor invasion of adjacent organs.
†Histology: Differentiated, papillary or tubular adenocarcinoma; undifferentiated, poorly differentiated or mucinous adenocarcinoma, or 
signet ring cell carcinoma.
IgG, Immunoglobulin G.
Table 1. Serum concentration of total IgG, IgG1, IgG2, 
IgG3, and IgG4 in control and gastric cancer patients
Control Gastric cancer patients P value
Total IgG 1037 ± 293.3 905.1 ± 412.2 0.032
IgG1 588.5 ± 318.9 539.8 ± 397.6 0.29
IgG2 281.4 ± 139.9 248.3 ± 141.9 0.21
IgG3 41.9 ± 31.6 32.6 ± 26.3 0.082
IgG4 90.2 ± 65.2 84.3 ± 80.2 0.38
All results expressed as means ± SD. IgG, Immunoglobulin G. 
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Table 3. The serum concentration of each IgG subclass, 
pre- and post-operation, for patients with gastric  
cancer
IgG subclass Preoperative Postoperative P value
Total IgG 991.0 ± 419.0 1071.0 ± 417.0 0.047
IgG1 605.3 ± 417.1 672.0 ± 417.1 0.04
IgG2 259.4 ± 154.3 245.6 ± 164.6 0.37
IgG3 33.8 ± 28.7 36.3 ± 25.9 0.33
IgG4 92.6 ± 85.7 121.6 ± 96.6 < 0.0001
All results expressed as means ± SD. IgG, Immunoglobulin G. 
Table 4. Association of various factors with dis-
ease-specific survival determined by Cox’s propor-
tional hazards model and a stepwise procedure
HR 95% CI P value
N (n0–n3)* 3.253 1.995 – 5.305 < 0.0001
Total IgG (high vs low) 0.3 0.093 – 0.967 0.044
*n0, no regional lymph node metastasis; n1, metastasis in 1–2 re-
gional lymph nodes; n2, metastasis in 3–6 regional lymph nodes; 
n3, metastasis in 7 or more regional lymph nodes.
CI, confidence interval; HR, hazard ratio; IgG, Immunoglobulin G.
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Fig. 1. Kaplan–Meier analysis of the effects of serum concentration of IgG on DSS in patients with gastric cancer. (a) The 5-year DSS rate 
was significantly lower in patients with low serum concentration of total IgG than those with a high serum concentration of total IgG (72.3% 
vs. 97.4%, P = 0.0077). (b) The 5-year DSS rate was significantly lower in patients with a low serum concentration of total IgG1 than 
those with a high serum concentration of total IgG1 (73.2% vs. 89.0%, P = 0.024). DSS, disease-specific survival; IgG, Immunoglobulin G.
patients with lymph node metastasis when compared 
with patients without lymph node metastasis (P = 0.025; 
Table 2). Serum concentration of IgG1 tended to be 
lower in patients with lymph node metastasis than in 
those without lymph node metastasis (P = 0.096; Table 
2). Furthermore, the total serum concentration of IgG in 
patients with stage III/IV tumors was significantly lower 
when compared with patients with stage I/II tumors (P = 
0.0085; Table 2). The serum concentrations of IgG1 and 
IgG3 in stage III/IV patients tended to be lower when 
compared with stage I/II patients (Table 2). 
Serum concentration of IgG before and after the 
patient’s operation
We then determined the serum concentration of IgG 1 
month after each patient’s operation (Table 3). Postoper-
ative serum concentrations of total IgG, IgG1, and IgG4 
were significantly higher than preoperative serum con-
centrations of total IgG, IgG1, and IgG4, respectively. 
Serum concentration of IgG and prognosis
Finally, we evaluated the correlation between IgG serum 
concentration and the prognosis of the gastric cancer pa-
tients. To determine an optimal cutoff value, we applied 
ROC analysis and used the serum concentration that 
had the highest Youden index (sensitivity + specificity 
– 1) as the optimal cutoff value. Optimal cutoff values 
were 933.4 [area under the curve (AUC) 0.715, 95% con-
fidence interval (CI) 0.579–0.851], 422.6 (AUC 0.654, 
95% CI 0.512–0.796), 202.4 (AUC 0.619, 95% CI 0.478–
0.759), 32.15 (AUC 0.545, 95% CI 0.391–0.699), and 
122.1 (AUC 0.593, 95% CI 0.469–0.716) for total IgG, 
IgG1, IgG2, IgG3, and IgG4, respectively. Using these 
cutoffs, the 100 patients were classified into two groups: 
a high-concentration group, ≥ optimal cutoff value, and 
a low-concentration group, < optimal cutoff value. The 
5-year DSS rates were 97.4% and 72.3% in patients with 
high or low concentrations of total IgG, respectively, 
and the differences were statistically significant (P < 
0.0077, Fig. 1a). The 5-year DSS rates were 89.0% and 
73.2% in patients with a high or low concentration of 
a b
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IgG1, respectively, with the differences being statistical-
ly significant (P = 0.024, Fig. 1b). 5-year DSS rates were 
88.3% and 71.3%, 91.9% and 74.2%, 90.0% and 78.1% in 
patients with a high or low concentration of IgG2, IgG3, 
and IgG4, respectively. Although there was not a statisti-
cally significant difference for IgG2 (P = 0.13), IgG3 (P 
= 0.11), and IgG4 (P = 0.088), the prognosis of patients 
with a high concentration of these IgGs was better when 
compared with patients with low IgG2, IgG3, and IgG4 
concentrations. Because only IgG1 was significantly 
related to prognosis of gastric cancer patient among four 
subclasses of IgG, we determined the prognostic signifi-
cance of IgG1 to total IgG ratio. ROC analysis indicated 
that AUC of IgG1 to total IgG ratio was 0.58, which was 
lower than that of serum concentration of IgG1, showing 
that serum concentration of IgG1 is more useful than 
IgG1 to total IgG ratio to predict accurate prognosis of 
gastric cancer patients. Using Cox’s proportional haz-
ards model and a stepwise procedure, we found that the 
serum concentration of total IgG and lymph node metas-
tasis were independently prognostic for poorer survival 
(Table 4). 
The correlation between serum concentration of 
total IgG and CEA
The carcinoembryonic antigen (CEA) is the tumor 
marker that is the most frequently used for gastric cancer 
patients. The 5-year survival rates of patients with either 
high CEA (≥ 5 ng/mL) or normal CEA (< 5 ng/mL) were 
43.8% (n = 22) and 93.6% (n = 78), respectively, and the 
difference was statistically significant (P < 0.0001). We 
determined the correlation between CEA and total IgG 
serum concentration and found that there is no correla-
tion between serum concentration of total IgG and CEA 
(r = –0.065, P = 0.53, Fig. 2). 
The presence of CD138-positive plasma cells in 
the tissue of gastric cancer
Finally, we determined the number of plasma cells, de-
fined as CD138-positive cells, in the tissue of non-can-
cerous gastric mucosa and the gastric cancers. The 
number of plasma cells were 106.5 ± 54.4 and 85.9 ± 
51.5 in normal gastric mucosa and gastric cancer tissue, 
respectively. The number of plasma cells was signifi-
cantly lower in gastric cancer tissue when compared 
with non-cancerous gastric mucosa (P = 0.0079).
DISCUSSION
This study has shown that the serum concentration of 
total IgG was significantly lower in gastric cancer pa-
tients compared with control patients. For all subclasses 
of IgG, their concentrations were also lower in gastric 
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Fig. 2. Correlation between serum concentration of total IgG and 
CEA. There was no significant correlation between serum concen-
tration of total IgG and CEA (r = –0.065, P = 0.53). IgG, Immuno-
globulin G; CEA, carcinoembryonic antigen.
cancer patients compared with control patients, although 
the differences were not statistically significant. These 
results indicate that antibody-mediated immunity is im-
paired in the patients with gastric cancer. This impair-
ment seems to be dependent on the level of tumor bur-
den as lower serum concentrations of IgG were related to 
the presence of lymph node metastasis and an advanced 
stage of disease. An important finding is that a decrease 
in the serum concentration of IgG was closely correlated 
to the poor prognosis of gastric cancer patients. In this 
regard, Jerome et al. have described a long-term survi-
vor of breast cancer whose tumor strongly expressed 
mucin-1 (MUC-1); a transmembrane glycoprotein that 
results in circulating anti-mucin antibodies of both the 
IgM and IgG isotypes. These antibodies are not found 
in control patients, which indicated that the level of the 
patient’s anti-mucin immunity may have helped protect 
her against recurrent tumor.20 Furthermore, Coronella 
et al. have demonstrated that an in situ antigen-driven 
oligoclonal B cell responded to a variety of tumor- and 
breast-associated antigens.21 These studies clearly indi-
cate that an antibody-mediated immune response is also 
important in tumor immunity. Therefore, the correlation 
between the serum concentration of IgG and the prog-
nosis of gastric cancer patients observed in the current 
study may be due to impairment of antibody-mediated 
immunity. Among four subclasses of IgG, on the other 
hand, IgG1 seems to play the most important roles in tu-
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mor immunity, because a significant difference in prog-
nosis was observed only in IgG1. In this regard, IgG1 is 
capable of eliciting antibody-dependent cell-mediated 
cytotoxicity, antibody-dependent cellular phagocytosis, 
and complement-dependent cytotoxicity. Because IgG1 
is normally the most abundant subclass of all the IgGs, a 
lack of IgG1, which is observed in a variety of primary 
and secondary antibody deficiencies, can result in a de-
crease of total IgG. An IgG1 deficiency, and sometimes 
in combination with other IgG subclass deficiencies, is 
associated with recurrent infections.22 Therefore, in the 
current study it was likely that the low levels of IgG1 
indicated impaired antibody-mediated immunity in the 
gastric cancer patients. 
 Because plasma cells are the only cells that can pro-
duce IgG, we measured the number of plasma cells in 
non-cancerous gastric mucosa and in the gastric cancer 
tissue by immunohistochemistry using the anti-CD138 
antibody. From this we sought to determine the de-
tailed mechanisms responsible for the decreased serum 
concentration of IgG. The number of CD138-positive 
plasma cells was significantly lower in the gastric cancer 
tissue compared with non-cancerous gastric mucosa. 
Therefore, a decrease in CD138-positive plasma cells in 
the gastric cancer tissue may be correlated with a de-
crease in the serum concentration of IgG. Unfortunately, 
the detailed mechanisms responsible for the decrease in 
the number of CD138-positive plasma cells in the gastric 
cancer tissue remain unclear; further investigation is re-
quired. 
 It is easy to measure the serum concentration of 
IgG. The serum concentration of total IgG is signifi-
cantly related to the prognosis of gastric cancer patients. 
Furthermore, multivariate analysis indicated that the 
serum concentration of total IgG was an independent 
prognostic indicator for poorer survival. Therefore, 
the serum concentration of total IgG can be used as a 
prognostic indicator. In this regard, CEA is usually used 
routinely in the clinic and it has already been demon-
strated that CEA is closely related to the prognosis of 
gastric cancer patients.23 Our results indicate that there 
was no statistical correlation between the serum concen-
tration of CEA and total IgG, indicating that the serum 
concentration of total IgG may be useful as a prognostic 
indicator, regardless of the serum concentration of CEA. 
The close correlation between the decreased serum con-
centration of IgG and poor patient prognosis suggests 
that antibody-mediated immunity may be a target for 
the treatment of gastric cancer. Moreover, the serum 
concentration of IgG may be useful in predicting tumor 
recurrence and patient prognosis; however, to confirm 
both of these hypotheses, additional studies are needed.
 To our knowledge, this study is the first to show that 
the serum concentration of IgG is decreased in gastric 
cancer tissue and is associated with a poor prognosis 
for gastric cancer patients. Impaired antibody-mediated 
immunity may be one of the main mechanisms respon-
sible for the progression of gastric cancer and a better 
understanding of these mechanisms may lead to novel 
treatments.
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